Perspective Therapeutics Advances Cancer Treatment with New Phase 1/2a Study
Perspective Therapeutics, Inc. announced that the first patient diagnosed with meningioma has been dosed with the radiopharmaceutical [212Pb]VMT-α-NET as part of its Phase 1/2a clinical study, aimed at evaluating the treatment’s safety and anti-tumor efficacy. Meningiomas, the most common primary brain tumors in adults, represent a significant challenge due to limited treatment options for patients with recurrent or inoperable cases. The company is exploring the use of [212Pb]VMT-α-NET, which targets tumors expressing somatostatin receptor subtype 2 (SSTR2). Initial efficacy data from this study is expected in 2026, aligning with the company’s strategy to expand its cancer treatment portfolio.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.manilatimes.net/2026/06/03/tmt-newswire/globenewswire/perspective-therapeutics-expands-therapeutic-focus-areas-first-patient-dosed-with-212pbvmt-net-in-the-meningioma-cohort-of-a-phase-12a-study/2357644
